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ABSTRACT 
Objective: Parkinson’s disease (PD) is the second most neurodegenerative disorder. Bacopa monnieri (BM), an Indian herb extensively used in 
Ayurveda, used in treatments related to neurological complications was used now in our study. 
Methods: In the present experiment, rats were divided into four groups of six in each group: group 1 received saline water, group 2 received 
rotenone (RT) through i.p. for 60 days to induce PD, group 3 received for 20 days orally before induction of PD and group 4 received Levodopa 
(Reference drug; LD) orally.  
Results: The levels Dopamine (DA), Serotonin (5-HT), Epineprine (EP), Nor-epineprine (NEP) were decreased and Monoamine oxidase (MAO) 
activity was increased in different brain regions such as Cerebral cortex (CC), Cerebellum (CB), Mid brain (MB) and Pons medulla (PM) during 
induced PD compared with controls. These results were reversed after treatment with ethanolic extract of BM on par with reference drug (LD).  
Conclusion: Our results suggest the ability of BM extract to modulate catecholamine system in different brain regions of RT induced rodent model 
of PD and thus offers protection. When compared overall the BM is better than the LD drug. The BM may provide a platform for future drug 
discoveries and novel treatment strategies in PD and can act as antiparkinsonian agent.  
Keywords: Parkinson’s disease (PD), Bacopa monnieri (BM), Rotenone (RT), Levodopa (LD), Dopamine (DA), Serotonin (5-HT), Epineprine (EP), 
Nor-epineprine (NEP) and Monoamine oxidase (MAO). 
 
INTRODUCTION 
PD is the second most common progressive neurodegenerative 
disease after Alzheimer’s disease. PD is characterized by difficulties 
in movement control. Its classic symptoms include resting tremor, 
inability to start movements, rigidity, and difficulties in maintaining 
gait. PD results from the slow degeneration of dopaminergic 
neurons in the pars compacta of the substantia nigra and 
subsequent reduction of the modulatory actions of dopamine in the 
striatum. The etiology of PD remains unknown and no disease-
modifying drugs are available. Thus, the need for more information 
on the pathogenesis of PD is obvious. There is considerable evidence 
suggesting that mitochondrial dysfunction and oxidative damages 
may play a role in the pathogenesis of PD. Among the toxic animal 
models of PD, chronic systemic exposure of rotenone represents one 
of the most recently used approaches. (Betarbet et al., 2000). It is 
highly lipophilic and readily gains access to all organs (Talpade et al., 
2000) and functions as Complex I mitochondrial inhibitor. The 
chronic exposure to rotenone causes highly selective nigrostriatal 
dopaminergic degeneration, the characteristic feature of PD (Betarbet et 
al., 2000; Alam and Schmidt, 2002; Sherer et al., 2002). It develops slow 
onset of PD symptoms that makes suitable to study neuroprotective 
strategies (Sherer et al., 2003; Schmidt and Alam, 2006).  
Chronic use of current anti-parkinsonian medications including 
Levodopa therapy causes disabling abnormal involuntary 
movements known as drug-induced dyskinesias in the majority of 
PD patients (Deogaonkar and Subramanian, 2005). Hence there is a 
need to discover newer pharmacologically active agents obtained 
from natural sources as medicinal plant extracts. Several agents 
were suggested to modulate the cellular energy metabolism and 
could exert antioxidative effects. Agents that have shown to be 
beneficial in animal models of PD include creatine, Ginkgo biloba 
leaves extract (Bastianetto et al., 2002), Vicia faba beans (Shetty et 
al., 2002) coenzyme Q10
MATERIALS AND METHODS 
, nicotinamide, and acetyl-L-carnitine. 
Bacopa monnieri (called Brahmi in Sanskrit); an ayurvedic medicinal 
plant used as a brain tonic, can be used in this PD treatment. Its 
ethanolic extract contains a mixture of triterpenoid saponins 
designated as bacosides A and B (Chatterjee et al., 1963, 1965). 
Several studies have reported its pharmacological roles as memory 
enhancer (Bhattacharya et al., 2000), cognition-enhancer, (Das et al., 
2002), antidepressant and also antioxidant properties (Sairam et al., 
2001). In the present study Bacopa monnieri (BM) was used to study 
neuroprotection of PD.  
Collection of plant material 
Bacopa monnieri plant used in this work was collected in bulk from 
Tirumala Hills, Andhra Pradesh in India and authenticated by 
qualified botanist at Department of Botany, Sri Venkateswara 
University, Tirupati, Andhra Pradesh in India.  
Extract Preparation: 
The whole plant (including roots) of B. monnieri was dried in shade, 
and then powdered plant material was macerate with ethanol for 7 
days. The plant material was percolated with circulating 95% 
ethanol (200 ml) for three rounds. The residue was extracted twice 
using the same procedure. The extract was filtrated and 
concentrated under reduced pressure in the Buchi rotavapour 
yielding a greenish-black sticky residue. Finally the extract was 
freeze- dried and was used for further studies.  
Experimental design: 
The present work was conducted on male Wistar rats weighing 
150±25g, they were maintained at a temperature of 25±2⁰C and 
relative humidity of 45-55% with 12:12 h dark: light cycle. The rats 
were maintained according to the ethical guidelines for animal 
protection and welfare bearing no.04a/a/CPCSEA/IAEC/08-
09/SVU/zool/WR-GS/dt.1.9.2009. The rats were divided into 4 
groups each consisted of 6 rats.  
Group I: Served as normal control group, Oil (sunflower oil) was 
injected as vehicle to the control rats (1 ml/kg) of 1.0 ml/kg/day i.p. 
for 60 days. 
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Group II: Rotenone (RT) emulsified in sunflower oil at 2.5 mg/ml 
was given intraperitoneally once a day at 1 ml/kg for 60 days (Alam 
and Schmidt, 2002), which induces PD. 
Group III: RT-induced PD rats were treated with BM extract with a 
dose of 180 mg/kg/day orally for 80 days, started before 20 days 
from induction of PD. 
Group IV: RT -induced PD rats were treated with Levodopa 
(reference control) with a dose of 10 mg/kg/day orally started after 
20 days from induction of PD (Alam and Schmidt, 2004). 
The development of Parkinson’s disease was detected after 20 days 
from induction with rotenone, by occurrence of tremors and 
exhibiting specific symptoms such as bradykinesia and rigidity in 
rats. The treatment with BM extract was started 20 days before 
induction of PD and LD was started after 20 days from induction of 
PD and continued for 60 days.  
After stipulated duration, the animals were sacrificed by cervical 
dislocation and the brain regions [Cerebral cortex (CC), Cerebellum 
(CB), Mid brain(MB) and Pons-Medulla (PM)] were immediately 
isolated, frozen in liquid nitrogen and were stored at -40⁰C until 
further analysis. 
Biochemical Analysis 
Epinephrine (EP), Nor-epinephrine (NE) and dopamine (DA) and 5-
HT were estimated in all the brain regions were estimated by the 
method of Kari et al. (1978) and Monoamine oxidase (MAO) activity 
was estimated by the method of Green and Haughton (1961).  
Statistical Analyses 
Results are presented as mean ± SEM. One-way analysis of variance 
(ANOVA) followed by Student–Newman–Keuls (SNK) test was used 
to compare differences between means in more than two groups. A 
probability value of < 0.05 was considered to be statistically 
significant. All statistical analysis were performed using the SPSS 
statistical software package version 11.5. 
RESULTS 
The levels of biogenic amines, viz. dopamine (DA), norepinephrine 
(NE), epinephrine (EP), 5-hydroxytryptamine (5-HT), and the 
content of the enzyme monomaine oxidase (MAO) were estimated in 
different brain regions Cerbral cortex (CC), Cerebellum (CB), Mid 
brain (MB) and Pons medulla (PM) of control and experimental rats 
were represented in (Table 1, 2, 3 and 4). 
  
Table 1: Changes in the Nor epinephrine (NE) content in different brain regions of rats during RT-induced PD and on pretreatment with 
ethanolic extract of BM and treatment with LD. (Values are expressed in µg of Nor epinephrine/g wet wt of tissue) 






























































Table 2: Changes in the Epinephrine (EP) content in different brain regions of rats during RT-induced PD and on pretreatment with 
ethanolic extract of BM and treatment with LD 





























































 (Values are expressed in µg of Epinephrine/g wet wt of tissue) 
 
DISCUSSION 
Dopamine, along with the neurotransmitters norepinephrine and 
epinephrine, forms part of a system called the catecholamine 
system. Since these three monoamines play a pivatol role in motor 
control, so enhancing the catecholaminergic can be considered as 
one of the preferred method to reduce the Parkinson's symptoms 
and to improve overall health. All of these neurotransmitter 
pathways play a crucial role in the emotional well-being of an 
individual given their linkages to neurobehavioral processes as 
emotion, mood and cognation (Aarsland, 2006). Chronic use of 
current anti-parkinsonian medications causes disabling abnormal 
involuntary movements known as drug-induced dyskinesias (DID) 
in majority of patients with advanced Parkinson’s disease (PD) that 
are expensive and difficult to treat.  
However, anticonvulsant treatment with herbal medicines has not 
received much attention. The present study was aimed to know the 
effect of ethanolic extract of BM on induced PD, with the particular 
reference to catecholaminergic system. 
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Table 3: Changes in the Dopamine (DA) content in different brain regions of rats during RT-induced PD and on pretreatment with 
ethanolic extract of BM and treatment with LD.(Values are expressed in µg of Dopamine/g wet wt of tissue) 






























































Table 4: Changes in the 5-Hydroxytryptamine (5-HT) content in different brain regions of rats during RT-induced PD and on pretreatment 
with ethanolic extract of BM and treatment with LD 





























































(Values are expressed in µg of 5-Hydroxytryptamine /g wet wt of tissue) 
 
Table 5: Changes in the Monoamine oxidase (MAO) activity in different brain regions of rats during RT-induced PD and on pretreatment 
with ethanolic extract of BM and treatment with LD 





























































(Values are expressed in µ moles of p-hydroxyphenyl acetaldehyde formed/mg protein/hr). All the values are expressed in Mean ± SEM of six individual 
observations, * Values with the same superscript is significant at p<0.05 compared with control, # Values with the same superscript is significant at 
p<0.05 compared with PD rats, Values in ‘( )’ paranthesis are % change over saline control, Values in ‘[ ]’ paranthesis are % change over RT induced PD. 
In RT-induced rats, DA, NE, EP, 5-HT levels (P < 0.05) were signi ficantly depleted, whereas MAO activity (P < 0.05) was elevated in all the brain regions, 
when compared with control rats. Pretreatment with BM extract and treatment with LD caused significant elevation of DA, NE, EP,5-HT levels (P < 0.05) 
and depletion of MAO activity (P < 0.05) was observed in different brain regions, when compared to RT induced PD rats. 
  
In the present study, NE levels were decreased in RT-induced rats 
may be due to the loss of 50% of neurons in PD (Kellstein et al., 
1988). Similarly EP levels were also decreased (Ahlskog et al., 1996) 
during RT-induced PD (Ahlskog et al., 1996). DA levels and levels of 
5-HT (Rao et al., 2007) were decreased in RT-induced rats. In the 
present study NE, EP, DA and 5-HT levels increased significantly in 
pretreated BM and LD treated RT-induced rats compared to the RT-
induced rats. Sheikh et al. (2007) also have reported significant 
elevation in NE, DA and 5-HT levels in cortex and levels of NE and 5-
HT in hippocampus when treated with BM in acute and chronic 
unpredictable stress. On par with the decreased monoamines levels 
one of the main metabolizing enzymes monoamine oxidase (MAO) 
was found to be increased in all areas of rat brain during RT-induced 
Parkinson’s disease. Which suggest that the MAO is partially 
responsible for the metabolism of catecholamines and hence the rate 
of catecholamine depletion after synthesis/inhibition can be used as 
an index of catecholamine turnover (Brodie et al., 1966). The major 
problem encountered with Parkinson's is the degeneration of the 
dopaminergic system, leading to lowered dopamine levels. Thus 
dopamine levels, when abnormally low, due to degeneration of the 
dopamine system in the brain, leads to the loss of motor control and 
other conditions associated with Parkinson's disease. The most 
prominent symptoms of PD reflect deficits in motor function, such as 
tremors, postural disturbance, and difficulty in initiating voluntary 
movements, it is clear that catecholamine tract alterations had 
played a crucial role in the control of movement during induced PD. 
As in case of RT induced PD rats, overall catecholamine system is 
reduced when compared to control rats due to progression of 
disease. The main motor symptoms of PD as rigidity/tremors and 
muscle fatigness may be due to the abnormal increase of 
Acetylcholine (Ach) content in PD. The loss of dopaminergic 
inhibition for increased cholinergic activity in the striatum causes an 
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imbalance between dopaminergic and cholinergic modulation of the 
striatal output to the motor program may be due to increased level 
of ACh which causes overactivity and due to continuous stimulation 
without inhibition leading to the characteristic symptoms of tremor, 
rigidity and muscle fatigness leading to postural instability. As in our 
previous study (Swathi et al., 2013) the ACh levels were decreased 
significantly in pretreated BM and LD treated RT-induced rats 
compared to the RT-induced rats showing the rescuing effect of BM. 
Decrease in Ach levels shows the balance with DA was maintained, 
indicating increase in DA content when treated with BM extract to 
PD induced rats.  
It was recently demonstrated that a moderate level of complex I 
inhibition characteristic for PD leads to significant ROS formation 
(Sipos et al., 2003). Dopaminergic neurons are also likely to face a 
higher baseline level of oxidative stress due to ROS formed from the 
degradation of dopamine. On par with the Levodopa, pretreatment 
with the extract of BM caused conspicuous augmentation in the 
levels of monoamines and decline in the levels of monoamine 
oxidase. Thus the BM extract caused due to the PD and thus offers 
antiparkin sonian effect by modulating the monoamine 
neurotransmitters in different regions of rat brain. It has been 
reported that BM extract the dopamine content was found to be 
increased significantly compared with RT, in order for normal 
dopaminergic neurons to survive, they may require more 
intrinsically increased antioxidant capacity than other neurons. 
Among all of this experimental therapeutic refinement as LD, the use 
of BM extract has been most successful in that it has been shown 
that BM extract may have naturally occurring antioxidant capacity 
for rescuing striatal neurons and prolonging the survival of PD 
induced rats. In our present investigation, midbrain region in RT 
induced rat found DA content to be decreased by 80.98%, which 
shows the progression of the disease, were as in BM pretreated rats 
showed decrease of 30.42% compared to controls which showed its 
recovering against PD. 
CONCLUSION 
The present findings coupled with the earlier reports clearly suggests 
that abatement of all the biogenic amines play a pivotal role in the 
neuronal damage during PD and the bioactive factors present in the BM 
offers protection against PD induced catecholaminergic abnormalities. 
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